iBio, Inc. (IBIO)
USD 2.4
(-0.83%)
USD 2.4
(-0.83%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 4.46 Million USD | -73.88% |
| 2023 | 17.07 Million USD | -38.57% |
| 2022 | 27.79 Million USD | -15.06% |
| 2021 | 32.72 Million USD | -0.57% |
| 2020 | 32.9 Million USD | 32.25% |
| 2019 | 24.88 Million USD | -0.79% |
| 2018 | 25.08 Million USD | -0.73% |
| 2017 | 25.26 Million USD | -0.67% |
| 2016 | 25.43 Million USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 1.7 Million USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 FY | 3.47 Million USD | -79.64% |
| 2024 Q1 | 16.6 Million USD | -2.76% |
| 2024 Q3 | 17.33 Million USD | 5.25% |
| 2024 Q2 | 16.46 Million USD | -0.81% |
| 2024 Q4 | 4.46 Million USD | -74.27% |
| 2023 Q1 | 26.68 Million USD | -3.99% |
| 2023 FY | 17.07 Million USD | -38.57% |
| 2023 Q2 | 20.39 Million USD | -23.55% |
| 2023 Q3 | 17.98 Million USD | -11.81% |
| 2023 Q4 | 17.07 Million USD | -5.09% |
| 2022 Q1 | 35.63 Million USD | 8.91% |
| 2022 Q4 | 27.79 Million USD | 0.1% |
| 2022 Q2 | 27.7 Million USD | -22.25% |
| 2022 Q3 | 27.76 Million USD | 0.2% |
| 2022 FY | 27.79 Million USD | -15.06% |
| 2021 Q2 | 32.76 Million USD | -0.23% |
| 2021 Q1 | 32.83 Million USD | -0.22% |
| 2021 Q3 | 32.68 Million USD | -0.23% |
| 2021 Q4 | 32.72 Million USD | 0.12% |
| 2021 FY | 32.72 Million USD | -0.57% |
| 2020 Q1 | 32.37 Million USD | 30.1% |
| 2020 Q4 | 32.9 Million USD | -1.99% |
| 2020 Q3 | 33.57 Million USD | 3.7% |
| 2020 Q2 | 32.37 Million USD | 0.01% |
| 2020 FY | 32.9 Million USD | 32.25% |
| 2019 Q2 | 24.98 Million USD | -0.19% |
| 2019 FY | 24.88 Million USD | -0.79% |
| 2019 Q3 | 24.93 Million USD | -0.2% |
| 2019 Q4 | 24.88 Million USD | -0.2% |
| 2019 Q1 | 25.03 Million USD | -0.19% |
| 2018 FY | 25.08 Million USD | -0.73% |
| 2018 Q4 | 25.08 Million USD | -0.19% |
| 2018 Q3 | 25.12 Million USD | -0.18% |
| 2018 Q2 | 25.17 Million USD | -0.18% |
| 2018 Q1 | 25.22 Million USD | -0.17% |
| 2017 FY | 25.26 Million USD | -0.67% |
| 2017 Q2 | 25.35 Million USD | -0.17% |
| 2017 Q3 | 25.3 Million USD | -0.17% |
| 2017 Q4 | 25.26 Million USD | -0.17% |
| 2017 Q1 | 25.39 Million USD | -0.17% |
| 2016 Q3 | 25.47 Million USD | 0.0% |
| 2016 FY | 25.43 Million USD | 0.0% |
| 2016 Q4 | 25.43 Million USD | -0.16% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 Q3 | 325 Thousand USD | -3.85% |
| 2015 FY | - USD | 0.0% |
| 2015 Q2 | 338 Thousand USD | -39.1% |
| 2015 Q1 | 555 Thousand USD | 0.0% |
| 2015 Q4 | - USD | -100.0% |
| 2014 Q1 | 100 Thousand USD | -94.12% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | -100.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | 1.7 Million USD | 0.0% |
| 2013 FY | 1.7 Million USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | -801.01% |
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -1527.737% |
| Armata Pharmaceuticals, Inc. | 120.37 Million USD | 96.295% |
| Actinium Pharmaceuticals, Inc. | 2.11 Million USD | -111.074% |
| Azitra, Inc. | 885.94 Thousand USD | -403.416% |
| Can-Fite BioPharma Ltd. | 39.99 Thousand USD | -11050.279% |
| Chromocell Therapeutics Corporation | 1.26 Million USD | -251.545% |
| Calidi Biotherapeutics, Inc. | 7.23 Million USD | 38.364% |
| CEL-SCI Corporation | 13.57 Million USD | 67.138% |
| Lineage Cell Therapeutics, Inc. | 2.95 Million USD | -51.084% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 3.55 Million USD | -25.422% |
| Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | -83.215% |
| NovaBay Pharmaceuticals, Inc. | 2.74 Million USD | -62.774% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 312.7 Thousand USD | -1326.273% |
| BiomX Inc. | 15.09 Million USD | 70.448% |
| BiomX Inc. | 15.09 Million USD | 70.448% |
| Protalix BioTherapeutics, Inc. | 26.28 Million USD | 83.03% |
| Palatin Technologies, Inc. | 590.33 Thousand USD | -655.499% |
| Scorpius Holdings, Inc. | 14.04 Million USD | 68.238% |